Insights into P-Glycoprotein Inhibitors: New Inducers of Immunogenic Cell Death
Open accessThe DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
Doxorubicin is a strong inducer of immunogenic cell death (ICD), but it is ineffective in P-glycoprotein (Pgp)-expressing cells. Indeed, Pgp effluxes doxorubicin and impairs the immunesensitizing functions of calreticulin (CRT), an “eat-me” signal mediating ICD. It is unknown if classical Pgp inhibitors, designed to reverse chemoresistance, may restore ICD. We addressed this question by using Pgp-expressing cancer cells, treated with Tariquidar, a clinically approved Pgp inhibitor, and R-3 compound, a N,N-bis(alkanol)amine aryl ester derivative with the same potency of Tariquidar as Pgp inhibitor. In Pgp-expressing/doxorubicin-resistant cells, Tariquidar and R-3 increased doxorubicin accumulation and toxicity, reduced Pgp activity, and increased CRT translocation and ATP and HMGB1 release. Unexpectedly, only R-3 promoted phagocytosis by dendritic cells and activation of antitumor CD8+T-lymphocytes. Although Tariquidar did not alter the amount of Pgp present on cell surface, R-3 promoted Pgp internalization and ubiquitination, disrupting its interaction with CRT. Pgp knock-out restores doxorubicin-induced ICD in MDA-MB-231/DX cells that recapitulated the phenotype of R-3-treated cells. Our work demonstrates that plasma membrane-associated Pgp prevents a complete ICD notwithstanding the release of ATP and HMGB1, and the exposure of CRT. Pharmacological compounds reducing Pgp activity and amount may act as promising chemo- and immunesensitizing agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Recent research has revealed substantial posttranscriptional gene regulation of ABC transporters by miRNAs, underscoring the potential utilization of novel bioengineered miRNA agents to downregulate ABC transporter expression and affect intracellular drug accumulation [101].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [101]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“While various ABC transporter inhibitors have been shown to sensitize drug-resistant colon cancer cells to chemotherapy drugs in experimental models [98,99,100,101], the development of PGP as a therapeutic target for cancer in general has not been successful clinically [42].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [101]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Riganti, C., Castella, B., Kopecka, J., Campia, I., Coscia, M., Pescarmona, G., Bosia, A., Ghigo, D., & Massaia, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060975 · Cited by 50
Self-citationRetractedCalreticulin exposure dictates the immunogenicity of cancer cell death
Obeid, M., Tesniere, A., Ghiringhelli, F., Fimia, G. M., Apetoh, L., Perfettini, J.-L., Castedo, M., Mignot, G., Panaretakis, T., Casares, N., et al. (2007) · Nature Medicine · doi:10.1038/nm1523 · Cited by 3,216
Immunogenic cell death in cancer and infectious disease
Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L., & Kroemer, G. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2016.107 · Cited by 3,119
Ghiringhelli, F., Apetoh, L., Tesniere, A., Aymeric, L., Ma, Y., Ortiz, C., Vermaelen, K., Panaretakis, T., Mignot, G., Ullrich, E., et al. (2009) · Nature Medicine · doi:10.1038/nm.2028 · Cited by 1,898
Revisiting the role of ABC transporters in multidrug-resistant cancer
Robey, R. W., Pluchino, K. M., Hall, M. D., Fojo, A. T., Bates, S. E., & Gottesman, M. M. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0005-8 · Cited by 1,866 · cited 1×
“One of the main mechanisms involved in the resistance to doxorubicin is the presence on the cell surface of efflux proteins belonging to the ATP Binding Cassette (ABC) transporters, such as ATP Binding Cassette transporter B1 or P-glycoprotein (ABCB1/Pgp), ATP Binding Cassette transporter C1 or multidrug resistance-re…”
Consensus guidelines for the definition, detection and interpretation of immunogenic cell death
Galluzzi, L., Vitale, I., Warren, S., Adjemian, S., Agostinis, P., Martinez, A. B., Chan, T. A., Coukos, G., Demaria, S., Deutsch, E., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000337 · Cited by 1,119
Self-citationA novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death
Garg, A. D., Krysko, D. V., Verfaillie, T., Kaczmarek, A., Ferreira, G. B., Marysael, T., Rubio, N., Firczuk, M., Mathieu, C., Roebroek, A. J. M., et al. (2012) · The EMBO Journal · doi:10.1038/emboj.2011.497 · Cited by 800 · cited 3×
“By engaging the LDL receptor-related protein 1/CD91 receptor on DCs, the dimer CRT/ERp57 initiates the phagocytosis of dying cancer cells [6,7].”
BackgroundThree Decades of P-gp Inhibitors: Skimming Through Several Generations and Scaffolds
Palmeira, A., Sousa, E., H. Vasconcelos, M., & M. Pinto, M. (2012) · Current Medicinal Chemistry · doi:10.2174/092986712800167392 · Cited by 484
Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death
Garg, A. D., Galluzzi, L., Apetoh, L., Baert, T., Birge, R. B., Bravo-San Pedro, J. M., Breckpot, K., Brough, D., Chaurio, R., Cirone, M., et al. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00588 · Cited by 410
Self-citationTariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor
Fox, E., & Bates, S. E. (2007) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.7.4.447 · Cited by 350
Cited by
Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology
Vanmeerbeek, I., Sprooten, J., De Ruysscher, D., Tejpar, S., Vandenberghe, P., Fucikova, J., Spisek, R., Zitvogel, L., Kroemer, G., Galluzzi, L., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2019.1703449 · Cited by 227
Ashrafizadeh, M., Zarrabi, A., Hashemi, F., Moghadam, E. R., Hashemi, F., Entezari, M., Hushmandi, K., Mohammadinejad, R., & Najafi, M. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117984 · Cited by 162
Bian, M., Fan, R., Yang, Z., Chen, Y., Xu, Z., Lu, Y., & Liu, W. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01248 · Cited by 86
Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer
Haynes, J., & Manogaran, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26051988 · Cited by 82
“Recent research has revealed substantial posttranscriptional gene regulation of ABC transporters by miRNAs, underscoring the potential utilization of novel bioengineered miRNA agents to down-regulate ABC transporter expression and affect intracellular drug accumulation [101].”
Approaches to minimize the effects of P‐glycoprotein in drug transport: A review
Husain, A., Makadia, V., Valicherla, G. R., Riyazuddin, M., & Gayen, J. R. (2022) · Drug Development Research · doi:10.1002/ddr.21918 · Cited by 73
Role of ABCB1 in mediating chemoresistance of triple-negative breast cancers
El-Aziz, Y. S. A., Spillane, A. J., Jansson, P. J., & Sahni, S. (2021) · Bioscience Reports · doi:10.1042/bsr20204092 · Cited by 61
Cholesterol metabolism: At the cross road between cancer cells and immune environment
Kopecka, J., Godel, M., & Riganti, C. (2020) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2020.105876 · Cited by 61
Self-citationImmunogenic cell stress and death in the treatment of cancer
Pan, H., Liu, P., Zhao, L., Pan, Y., Mao, M., Kroemer, G., & Kepp, O. (2023) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2023.10.007 · Cited by 39
Gharehbaba, A. M., Omidi, Y., Barar, J., Eskandani, M., & Adibkia, K. (2024) · Biomaterials Advances · doi:10.1016/j.bioadv.2024.214081 · Cited by 35
Kim, R., & Kin, T. (2021) · Cancers · doi:10.3390/cancers13194756 · Cited by 34
Grabarnick, E., Andriyanov, A. V., Han, H., Eyal, S., & Barenholz, Y. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13122181 · Cited by 21
de Souza, T. A., Pereira, L. H. A., Alves, A. F., Dourado, D., Lins, J. D. S., Scotti, M. T., Scotti, L., Abreu, L. S., Tavares, J. F., & da Silva, M. S. (2024) · Pharmaceuticals · doi:10.3390/ph17101399 · Cited by 21
Cell Surface Transporters and Novel Drug Developments
Carmichael, N. S., & Day, P. J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.852938 · Cited by 18
Li, H., Zhang, S., Jia, Y.-H., Li, Q., Feng, Z., Zhang, S.-D., Zheng, W., Zhou, Y.-L., Li, L., Liu, X., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01862 · Cited by 18
Gharehbaba, A. M., Soltanmohammadi, F., Vandghanooni, S., Eskandani, M., & Adibkia, K. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118045 · Cited by 18
Strategies to Overcome Resistance to Immune-Based Therapies in Osteosarcoma
Hattinger, C. M., Salaroglio, I. C., Fantoni, L., Godel, M., Casotti, C., Kopecka, J., Scotlandi, K., Ibrahim, T., Riganti, C., & Serra, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24010799 · Cited by 16
Self-citationImmunology of Cell Death in Cancer Immunotherapy
Galluzzi, L., & Garg, A. D. (2021) · Cells · doi:10.3390/cells10051208 · Cited by 17
Braconi, L., Dei, S., Contino, M., Riganti, C., Bartolucci, G., Manetti, D., Romanelli, M. N., Perrone, M. G., Colabufo, N. A., Guglielmo, S., et al. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115716 · Cited by 14
Self-citationTFEB controls sensitivity to chemotherapy and immuno-killing in non-small cell lung cancer
Akman, M., Monteleone, C., Doronzo, G., Godel, M., Napoli, F., Merlini, A., Campani, V., Nele, V., Balmas, E., Chontorotzea, T., et al. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03142-4 · Cited by 16
Self-citationBraconi, L., Teodori, E., Contino, M., Riganti, C., Bartolucci, G., Manetti, D., Romanelli, M. N., Perrone, M. G., Colabufo, N. A., Guglielmo, S., et al. (2022) · ChemMedChem · doi:10.1002/cmdc.202200027 · Cited by 13
Self-citationYang, R., Guo, Z., Zhao, Y., Ma, L., Li, B., & Yang, C. (2021) · Cell Death Discovery · doi:10.1038/s41420-021-00590-1 · Cited by 13
Januškevičienė, I. (2024) · American Journal of Cancer Research · doi:10.62347/vnwh9165 · Cited by 11
Xu, J., Wang, Y., Williams, G. R., Zheng, Y., Zhang, Y., Wang, T., Du, C., Wang, Y., Wu, Y.-L., & Zhu, L. (2025) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2025.138100 · Cited by 9
Xu, F., Shan, X., Li, J., Li, J., Yuan, J., Zou, D., & Wang, M. (2025) · PLoS ONE · doi:10.1371/journal.pone.0322835 · Cited by 11
Nguyen, B. B., Lowe, N. M., Kellogg, S., Huang, K.-W., O'Toole, H. J., Hale, E. J., Shirure, V., Shergill, B., George, S. C., & Carney, R. P. (2026) · Advanced Healthcare Materials · doi:10.1002/adhm.202600019 · Cited by 3
Plant-derived diterpenes for breast cancer treatment: New perspectives and recent advances
Tomiotto‐Pellissier, F., Gonçalves, M. D., Silva, T. F., Concato, V. M., Bortoleti, B. T. D. S., Arakawa, N. S., Costa, I. C., Pavanelli, W. R., & Panis, C. (2022) · Studies in natural products chemistry · doi:10.1016/b978-0-323-91099-6.00011-6 · Cited by 5
Ping, L., He, Y., Gao, Y., Wang, X., Huang, C., Bai, B., & Huang, H. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12111840 · Cited by 6
Verma, A., Arora, A., Bhatt, A. N., Arya, M. B., Prasad, A. K., Parmar, V. S., & Dwarakanath, B. S. R. (2021) · Cancer Reports · doi:10.1002/cnr2.1326 · Cited by 5
Modeling Doxorubicin Pharmacokinetics in Multiple Myeloma Suggests Mechanism of Drug Resistance
Doshmanziari, R., Ros, F. D., Mazzucato, M., Pedersen, M. G., & VISENTIN, R. (2023) · IEEE Transactions on Biomedical Engineering · doi:10.1109/tbme.2023.3324017 · Cited by 4
Salaroglio, I. C., Stefanova, D., Teixeira, R. G., Oliveira, N. F. B., Ahmed, A., Fusi, F., Tzankova, V., Yordanov, Y., Machuqueiro, M., Saponara, S., et al. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107353 · Cited by 4
Self-citationRole of P-glycoprotein in Regulating the Efficacy, Toxicity and Pharmacokinetics of Yunaconitine
Li, X., Liang, Q., Wang, C., Qiu, H., Lin, T., Li, W., Zhang, R., Liu, Z., & Zhu, L. (2024) · Current Drug Metabolism · doi:10.2174/0113892002302427240801072910 · Cited by 4
Yishan, L. I. U., Elbadawy, M., Yamamoto, H., AUGOMAA, A., Ishihara, Y., Kaneda, M., Usui, T., & Sasaki, K. (2024) · Journal of Veterinary Medical Science · doi:10.1292/jvms.24-0344 · Cited by 4
Ahmed, N., Biswas, P., Mogal, M. R., Sarker, M. R., Tareq, M. M. I., Ahmed, S., Akter, M., Miah, M. T., Kundo, N. K., Hasan, M. N., et al. (2024) · Informatics in Medicine Unlocked · doi:10.1016/j.imu.2024.101493 · Cited by 2
Pleiotropic activities of nitric oxide-releasing doxorubicin on P-glycoprotein/ABCB1
Costamagna, C., Kopecka, J., & Riganti, C. (2020) · Journal of Molecular and Clinical Medicine · doi:10.31083/j.jmcm.2020.02.730 · Cited by 1
Self-citation(2023) · Jordan Journal of Biological Sciences · doi:10.54319/jjbs/160315 · Cited by 1
Akman, M., Monteleone, C., Doronzo, G., Godel, M., Napoli, F., Merlini, A., Campani, V., Nele, V., Balmas, E., Chontorotzea, T., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26507209
Self-citationde Souza, T. A. (2024) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Li, G., Zhang, P., Zhao, J., Xiong, Y., Yu, Z., Tian, Q., & Shu, C. (2026) · Chinese Chemical Letters · doi:10.1016/j.cclet.2026.112423
Kopecka, J., Godel, M., Dei, S., Giampietro, R., Belisario, D. C., Akman, M., Contino, M., Teodori, E., & Riganti, C. (2026) · Cells · doi:10.3390/cells15100866
Self-citationLiu, W.-B., Fu, X.-J., Li, N., Chen, B., Niu, J.-B., Yan-yan, W., Song, J., & Zhang, S. (2026) · Chinese Chemical Letters · doi:10.1016/j.cclet.2026.113260
Shen, S., Ma, Y., Zhao, J., Guo, L., Omer, A. M., Ouyang, X., & Wang, N. (2026) · ACS Applied Nano Materials · doi:10.1021/acsanm.6c02671
Metadata
- Authors
- Kopecka, J., Godel, M., Dei, S., Giampietro, R., Belisario, D. C., Akman, M., Contino, M., Teodori, E., & Riganti, C.
- Affiliations
- University of Turin (IT)
- University of Florence (IT)
- University of Bari Aldo Moro (IT)
- Corresponding author
- Riganti, Chiara
- ORCID
- Venue
- Cells
- Publisher
- MDPI AG
- Published
- 2020-04-22
- Volume
- 9
- Issue
- 4
- Pages
- 1033
- ISSN
- 2073-4409 (ISSN-L)
- PMC
- PMC7226521
- OpenAlex
- W3019388022
- Cited by
- 41
- References
- 47
- Citations by year
- 2026: 5 · 2025: 5 · 2024: 9 · 2023: 6 · 2022: 6 · 2021: 6 · 2020: 4
- FWCI
- 1.99
- Type
- journal article
- Language
- en
- Update notices
- correction (2020-04-22)
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Cells (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Florence Research (University of Florence) (submittedVersion, other-oa)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion, other-oa)
- Funders
- Associazione Italiana per la Ricerca sul Cancro (IG21408)
- Topics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- P-glycoprotein inhibitors, immunogenic cell death, doxorubicin resistance, tariquidar, calreticulin, ubiquitination, dendritic cell phagocytosis, CD8+ T cells, HMGB1, ATP release, chemoresistance reversal
- MeSH terms
- Immunogenic Cell Death, Doxorubicin, Endocytosis, Esters, Humans, Kinetics, Quinolines, Apoptosis, Drug Resistance, Neoplasm, ATP Binding Cassette Transporter, Subfamily B, Member 1, Calreticulin, Cell Line, Tumor, Ubiquitination, Proteolysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.